Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinically Relevant Solution for the Hypothermic Storage and Transportation of Human Multipotent Mesenchymal Stromal Cells

Y. Petrenko, M. Chudickova, I. Vackova, T. Groh, E. Kosnarova, J. Cejkova, K. Turnovcova, A. Petrenko, E. Sykova, S. Kubinova,

. 2019 ; 2019 (-) : 5909524. [pub] 20190120

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19013312

The wide use of human multipotent mesenchymal stromal cells (MSCs) in clinical trials requires a full-scale safety and identity evaluation of the cellular product and subsequent transportation between research/medical centres. This necessitates the prolonged hypothermic storage of cells prior to application. The development of new, nontoxic, and efficient media, providing high viability and well-preserved therapeutic properties of MSCs during hypothermic storage, is highly relevant for a successful clinical outcome. In this study, a simple and effective trehalose-based solution was developed for the hypothermic storage of human bone marrow MSC suspensions for further clinical applications. Human bone marrow MSCs were stored at 4°C for 24, 48, and 72 hrs in the developed buffered trehalose solution and compared to several research and clinical grade media: Plasma-Lyte® 148, HypoThermosol® FRS, and Ringer's solution. After the storage, the preservation of viability, identity, and therapeutically associated properties of MSCs were assessed. The hypothermic storage of MSCs in the new buffered trehalose solution provided significantly higher MSC recovery rates and ability of cells for attachment and further proliferation, compared to Plasma-Lyte® 148 and Ringer's solution, and was comparable to research-grade HypoThermosol® FRS. There were no differences in the immunophenotype, osteogenic, and adipogenic differentiation and the immunomodulatory properties of MSCs after 72 hrs of cold storage in these solutions. The obtained results together with the confirmed therapeutic properties of trehalose previously described provide sufficient evidence that the developed trehalose medium can be applied as a low-cost and efficient solution for the hypothermic storage of MSC suspensions, with a high potential for translation into clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013312
003      
CZ-PrNML
005      
20190408131543.0
007      
ta
008      
190405s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2019/5909524 $2 doi
035    __
$a (PubMed)30805009
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Petrenko, Yuriy $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
245    10
$a Clinically Relevant Solution for the Hypothermic Storage and Transportation of Human Multipotent Mesenchymal Stromal Cells / $c Y. Petrenko, M. Chudickova, I. Vackova, T. Groh, E. Kosnarova, J. Cejkova, K. Turnovcova, A. Petrenko, E. Sykova, S. Kubinova,
520    9_
$a The wide use of human multipotent mesenchymal stromal cells (MSCs) in clinical trials requires a full-scale safety and identity evaluation of the cellular product and subsequent transportation between research/medical centres. This necessitates the prolonged hypothermic storage of cells prior to application. The development of new, nontoxic, and efficient media, providing high viability and well-preserved therapeutic properties of MSCs during hypothermic storage, is highly relevant for a successful clinical outcome. In this study, a simple and effective trehalose-based solution was developed for the hypothermic storage of human bone marrow MSC suspensions for further clinical applications. Human bone marrow MSCs were stored at 4°C for 24, 48, and 72 hrs in the developed buffered trehalose solution and compared to several research and clinical grade media: Plasma-Lyte® 148, HypoThermosol® FRS, and Ringer's solution. After the storage, the preservation of viability, identity, and therapeutically associated properties of MSCs were assessed. The hypothermic storage of MSCs in the new buffered trehalose solution provided significantly higher MSC recovery rates and ability of cells for attachment and further proliferation, compared to Plasma-Lyte® 148 and Ringer's solution, and was comparable to research-grade HypoThermosol® FRS. There were no differences in the immunophenotype, osteogenic, and adipogenic differentiation and the immunomodulatory properties of MSCs after 72 hrs of cold storage in these solutions. The obtained results together with the confirmed therapeutic properties of trehalose previously described provide sufficient evidence that the developed trehalose medium can be applied as a low-cost and efficient solution for the hypothermic storage of MSC suspensions, with a high potential for translation into clinical practice.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chudickova, Milada $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Vackova, Irena $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Groh, Tomas $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Bioinova Ltd., Prague, Czech Republic.
700    1_
$a Kosnarova, Eliska $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Bioinova Ltd., Prague, Czech Republic.
700    1_
$a Cejkova, Jitka $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Turnovcova, Karolina $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Petrenko, Alexander $u Institute for Problems of Cryobiology and Cryomedicine, National Academy of Sciences of Ukraine, Kharkiv, Ukraine.
700    1_
$a Sykova, Eva $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia.
700    1_
$a Kubinova, Sarka $u Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
773    0_
$w MED00188142 $t Stem cells international $x 1687-966X $g Roč. 2019, č. - (2019), s. 5909524
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30805009 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190408131556 $b ABA008
999    __
$a ind $b bmc $g 1392622 $s 1051617
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 2019 $c - $d 5909524 $e 20190120 $i 1687-966X $m Stem cells international $n Stem cells int $x MED00188142
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace